Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis

Company Overview

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.

The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS). NurOwn has received orphan drug designations in multiple jurisdictions and is being evaluated in a pivotal clinical program. In addition to ALS, BrainStorm is exploring potential applications of its cell therapy platform in other neurodegenerative disorders such as multiple sclerosis and Parkinson’s disease.

Founded in 2000 and headquartered in Petach Tikva, Israel, BrainStorm maintains research and development operations as well as a current good manufacturing practice (cGMP) cell‐processing facility. The company also operates an office in New York City, facilitating collaborations with U.S. clinical sites and regulatory agencies. This infrastructure supports late‐stage trials and positions BrainStorm for potential commercial supply should regulatory approval be achieved.

BrainStorm collaborates with leading academic institutions and regulatory authorities to advance its clinical pipeline while maintaining robust data transparency. Guided by a management team with expertise in regenerative medicine, neurology and biopharmaceutical development, the company aims to address significant unmet medical needs in the global neurodegenerative disease market.

Key Stats

• Today's Range: $0.71 to $0.80
• 50-Day Range: $0.58 to $1.31
• 52-Week Range: $0.52 to $4.55
• Volume: 3,140 shs
• Average Volume: 570,611 shs
• Market Capitalization: $8.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Brainstorm Cell Therapeutics Stock Analysis - MarketRank™

Brainstorm Cell Therapeutics scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Brainstorm Cell Therapeutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Brainstorm Cell Therapeutics are expected to grow in the coming year, from ($3.01) to ($1.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Brainstorm Cell Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Brainstorm Cell Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.16% of the outstanding shares of Brainstorm Cell Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Brainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Brainstorm Cell Therapeutics has recently decreased by 19.27%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Brainstorm Cell Therapeutics does not currently pay a dividend.

Dividend Growth

Brainstorm Cell Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.66

Percentage of Shares Shorted

3.16% of the outstanding shares of Brainstorm Cell Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Brainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Brainstorm Cell Therapeutics has recently decreased by 19.27%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Brainstorm Cell Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.15% of the stock of Brainstorm Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 14.33% of the stock of Brainstorm Cell Therapeutics is held by institutions.

BCLI Stock Analysis - Frequently Asked Questions

How have BCLI shares performed this year?

Brainstorm Cell Therapeutics' stock was trading at $2.27 at the beginning of the year. Since then, BCLI shares have decreased by 64.8% and is now trading at $0.7997.

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) released its quarterly earnings data on Thursday, May, 15th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.07.
Read the conference call transcript.

When did Brainstorm Cell Therapeutics' stock split?

Shares of Brainstorm Cell Therapeutics reverse split on Tuesday, October 1st 2024.The 1-15 reverse split was announced on Thursday, September 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Brainstorm Cell Therapeutics' major shareholders?

Top institutional investors of Brainstorm Cell Therapeutics include Gunderson Capital Management Inc. (0.26%). Insiders that own company stock include Chaim Lebovits, Stacy Lindborg and Ibrahim B Dagher.
View institutional ownership trends.

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Brainstorm Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Brainstorm Cell Therapeutics investors own include CocaCola (KO), Organovo (ONVO), Cardium Therapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Protalix BioTherapeutics (PLX) and Isoray (ISR).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 9/10/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCLI
• CIK: 1137883
• Web: www.brainstorm-cell.com
• Phone: (201) 488-0460
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.62 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -519.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.21
• Quick Ratio: 0.21

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.36) per share
• Price / Book: -0.57

Miscellaneous

• Outstanding Shares: 11,035,000
• Free Float: 8,742,000
• Market Cap: $8.60 million
• Optionable: Optionable
• Beta: 0.15